OnabotulinumtoxinA 200U | Wholesale Per Vial
From $489.00 / vial
4.9 / 5.0 - 187 reviews
Select Products
The same trusted Allergan OnabotulinumtoxinA 200U vial formulation for hyperhidrosis, chronic migraine, masseter reduction, and other therapeutic indications
Botox® Therapeutic (OnabotulinumtoxinA) is the 200-unit vial formulation of Allergan's flagship botulinum toxin, specifically indicated for therapeutic applications beyond cosmetic use. While Botox Cosmetic (100U) targets frown lines, crow's feet, and forehead wrinkles, the 200U Therapeutic vial extends to FDA-approved indications including primary axillary hyperhidrosis, chronic migraine prophylaxis, overactive bladder, upper and lower limb spasticity, and cervical dystonia with additional off-label aesthetic uses including masseter reduction for facial slimming.
Also see: Botox Cosmetic | Official info: Allergan.com
Botox® Therapeutic (OnabotulinumtoxinA) is the 200-unit vial from Allergan designed for practitioners treating both aesthetic and medical indications in a single practice. Where the 100U Botox Cosmetic vial is optimized for facial aesthetic treatments glabellar lines, forehead wrinkles, crow's feet the 200U Therapeutic vial provides the greater unit volume required for hyperhidrosis protocols (50U per axilla), chronic migraine prevention (155U across 31 injection points), limb spasticity management, and overactive bladder.
For NYC practitioners who treat both cosmetic and medical patients, the 200U vial offers significant workflow efficiency: a single reconstitution can supply a complete hyperhidrosis session or an entire migraine prevention protocol minimizing waste and maximizing throughput without compromising Allergan's trusted formulation quality.
| Product Name | Botox® Therapeutic |
| Active Ingredient | OnabotulinumtoxinA (Botulinum Toxin Type A) |
| Vial Size | 200 units per vial |
| Manufacturer | Allergan Aesthetics (AbbVie) |
| FDA Approvals | Hyperhidrosis, Chronic Migraine, OAB, Spasticity, Cervical Dystonia |
| Onset of Action | 3–7 days; full effect at 2 weeks |
| Duration | 3–6 months (indication-dependent) |
| Administration | Intramuscular or intradermal injection by licensed practitioner only |
Initial neuromuscular blockade occurs. Sweating reduction begins in hyperhidrosis patients; migraine frequency reduction begins to emerge after the first treatment cycle.
Full effect established across all treated sites. Hyperhidrosis patients typically experience 82–87% reduction in sweat production. Masseter reduction begins with muscle atrophy becoming noticeable by month 1–2.
Effects gradually wear off as nerve regeneration occurs. Retreatment every 3–4 months for aesthetic indications; 12-week retreatment intervals are typical for migraine and hyperhidrosis protocols.
Wholesale prices listed per vial.
Pricing is subject to change. For licensed practitioners only.
Your licensed Sculptra NYC practitioner assesses the therapeutic indication whether hyperhidrosis, chronic migraine, masseter hypertrophy, or another condition and designs a protocol to target the relevant anatomy with the appropriate dose per site. The 200U vial enables complete multi-site treatment within a single session without the need for multiple reconstitutions.
For hyperhidrosis: 50U per axilla administered as 10–15 intradermal injections per side. For masseter reduction: 20–30U per masseter administered as 2–4 intramuscular injection points. For migraine: 155U across 31 injection points following the PREEMPT protocol as prescribed. Procedures take 15–45 minutes depending on indication.
OnabotulinumtoxinA prevents the release of acetylcholine at the neuromuscular junction. In therapeutic use, this same mechanism blocks the autonomic nerve signals to eccrine sweat glands (hyperhidrosis), reduces muscle contraction in masseter and pericrania (migraine/masseter), and modulates detrusor overactivity (OAB).
Hyperhidrosis and migraine protocols are typically repeated every 12 weeks for sustained benefit. Masseter reduction may require 2–3 initial sessions spaced 3–4 months apart to achieve progressive muscle atrophy, with maintenance every 6–12 months thereafter. Your practitioner will tailor the schedule based on your response.
Botox Therapeutic is intended for licensed healthcare professionals who treat both aesthetic and medical patients. It is especially valuable for multi-specialty practices in New York City where a single practitioner may treat hyperhidrosis patients in the morning and perform masseter reduction or cosmetic neurotoxin treatments in the afternoon making the 200U vial a highly efficient choice for high-volume clinics.
Patients experiencing primary axillary hyperhidrosis, chronic migraine (≥15 headache days/month), masseter hypertrophy, or upper/lower limb spasticity may benefit from Botox Therapeutic as part of a comprehensive treatment protocol under physician supervision.
A consultation with a licensed Sculptra NYC specialist is required to determine candidacy. See Important Safety Information below.
Both contain the same active ingredient OnabotulinumtoxinA from Allergan but they differ in vial size and intended use. Botox Cosmetic comes in 50U and 100U vials and is specifically indicated for facial aesthetic treatments (glabellar lines, forehead wrinkles, crow's feet). Botox Therapeutic comes in a 200U vial and is FDA-approved for therapeutic indications including hyperhidrosis, chronic migraine, limb spasticity, overactive bladder, and cervical dystonia.
The FDA-approved protocol for primary axillary hyperhidrosis is 50 units per axilla (100 units total), administered as multiple intradermal injections across the affected area. The 200U Botox Therapeutic vial allows one complete bilateral hyperhidrosis session in a single reconstitution, plus remaining units for additional treatment areas if needed.
Yes, although masseter reduction is an off-label use. Botox is injected into the masseter muscle typically 20–30U per side to reduce muscle bulk over time, resulting in facial slimming, a softer jawline, and relief from teeth grinding (bruxism). Results improve over 2–3 treatment cycles spaced 3–4 months apart.
The FDA-approved chronic migraine protocol (PREEMPT) calls for 155U administered across 31 injection points every 12 weeks. Most patients notice a meaningful reduction in headache days per month after the second or third treatment cycle, with cumulative benefit improving over 6–12 months of consistent treatment.
Duration varies by indication: hyperhidrosis effects typically last 4–7 months, migraine prevention effects last approximately 12 weeks (hence the 12-week retreatment interval), and masseter reduction effects typically last 4–6 months initially, with longer maintenance intervals after several treatment cycles have achieved the desired muscle atrophy.
The gold standard 20+ years of proven safety and precision cosmetic results
From $267.00 / vial
Faster onset and broad diffusion preferred for large treatment areas
From $229.00 / vial
No complexing proteins precision-engineered purity for reduced antibody risk
From $249.00 / vial
Important Safety Information